Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
Karmila Abu BakarNor Asiah MohamadZsolt HodiTom McCullochAlun WilliamsMartin ChristianTim KeyJon Jin KimPublished in: Pediatric nephrology (Berlin, Germany) (2019)
Monitoring of tacrolimus IPV using the MAD may be a clinical marker for LACR. A threshold IPV of 26% can potentially be used as a therapeutic target pending further validation studies.